Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Sponsor: Abramson Cancer Center at Penn Medicine

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04691817

Patient View

This clinical trial assesses the safety and efficacy of combining tocilizumab and atezolizumab in treating advanced non-squamous NSCLC. Eligible participants are adults with Stage IV or recurrent NSCLC, previously treated with a checkpoint inhibitor. Interventions include atezolizumab (1200mg infusion) and tocilizumab (6mg/kg or 4mg/kg infusion). Participants must have an ECOG PS of 0-2.

Patient Parameters

Program Overview

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Eligibility Criteria

Inclusion Criteria

  • Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • Prior exposure to at least 1 line of therapy
  • Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
  • ECOG PS 0-2

Exclusion Criteria

  • Presence of a driver mutation that is susceptible to targeted therapy
  • No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
  • Other active invasive malignancy requiring ongoing therapy
  • Evidence of progressing or untreated brain metastases
  • Evidence or history of leptomeningeal disease
  • Uncontrolled tumor related pain
  • History of an autoimmune disease or IPF

Get This Program In Your Inbox

You can sign up and apply your patients for this program.